Abstract 388P
Background
Antiangiogenic drugs have demonstrated synergistic effect with chemotherapy in advanced triple negative breast cancer. Anlotinib is an oral multi-target tyrosine kinase inhibitor (TKI) that strongly inhibits VEGFR, PDGFR, FGFR, and c-kit. There have been no studies of compared differences in the efficacy of anlotinib and bevacizumab in MBC patients. This study was designed to evaluate the efficacy of anlotinib or bevacizumab when combined with chemotherapy for the second-line or subsequent treatment of HER-2-MBC.
Methods
As of April 2024, 106 patients were retrospectively reviewed. These included 50 and 56 patients in the anlotinib and bevacizumab plus chemotherapy groups, respectively. Anlotinib (12 mg qd. d1-14 q3w) was orally administered. Bevacizumab (10 mg/kg, q3w) was intravenously administered. Chemotherapy regimens consisted of capecitabine, docetaxel, nab-paclitaxel, or paclitaxel, with respective doses of 1,000 mg/m2 tiw d1-14 q3w, 75-100 mg/m2 iv. q3w, 260 mg/m2 iv. q3w, and 175 mg/m2 iv. q3w. The primary endpoint is PFS and secondary endpoints are ORR, DCR, and OS.
Results
The median follow-up intervals as of the cut-off deadline were 24.3 and 26.5 months in the anlotinib and bevacizumab groups, respectively. Of these patients, 58% exhibited HR-positive disease. There were no differences in patient age (P=0.07), ECOG status (P=0.43), or prior systematic treatment (P=0.16) when comparing two groups. In the anlotinib and bevacizumab groups, the respective ORRs were 42% and 33.9% (P > 0.05), while the DCRs were 86% and 69.6%. Patients in the anlotinib group exhibited significantly longer mPFS and mOS as compared to the bevacizumab group (PFS: 6.0 vs. 5.3 months, HR 0.636 [95% CI 0.412-0.981], P = 0.033; OS: 17.1 vs. 15.0 months, HR 0.581 [95% CI 0.3741-0.9017], P = 0.015). Subgroup analyses additionally revealed that patients who underwent a combination of anlotinib and taxane treatment achieved the longest PFS (7.0 months) and OS (18.3 months). The most frequently detected treatment-related adverse events were grade 1/2 events.
Conclusions
Anlotinib plus chemotherapy have shown favorable efficacy and acceptable safety profile in patients with advanced HER-2-negative MBC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
523P - A phase II study of intrapatient dose escalation of biweekly trifluridine/tipiracil plus bevacizumab for colorectal cancer (E-BiTS study)
Presenter: Munehiro Wakabayashi
Session: Poster session 15
524P - A phase II study of alpelisib, a PIK3CA inhibitor, and capecitabine in patients with metastatic colorectal cancer who failed two prior standard chemotherapies
Presenter: Ahreum Lim
Session: Poster session 15
525P - Final analysis of the JACCRO CC-16: Ramucirumab plus FOLFIRI for RAS wild-type mCRC refractory to anti-EGFR antibody
Presenter: Keiji Sugiyama
Session: Poster session 15
526P - Efficacy and safety of fruquintinib in refractory metastatic colorectal cancer: A FRESCO-2 subgroup analysis by age
Presenter: Maria Elena Elez Fernandez
Session: Poster session 15
527P - Effect of trifluridine/tipiracil (FTD/TPI) in combination with bevacizumab (bev) in patients treated in SUNLIGHT by clinical prognostic factors at baseline
Presenter: Josep Tabernero
Session: Poster session 15
529P - Evaluating metastatic disease sites as a prognostic marker in patients receiving sequential treatment with regorafenib and trifluridine/tipiracil for refractory colorectal cancer: Survival outcomes from the multicenter retrospective “ReTrITA” study
Presenter: Carlo Signorelli
Session: Poster session 15
530P - Real-world effectiveness and predictive biomarker analysis of TAS-102+bevacizumab vs. regorafenib vs. TAS-102 in metastatic colorectal cancer: A multicenter cohort study
Presenter: Andreas Seeber
Session: Poster session 15
531P - Prognostic value of liver metastases, KRAS mutations and race in colorectal cancer patients: A pooled analysis of third-line placebo-controlled trials from the ARCAD database
Presenter: Thierry André
Session: Poster session 15
532P - G-CSF secondary prophylaxis in patients (pts) with metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil (FTD/TPI): The GERCOR LONGBOARD study
Presenter: Jean-Baptiste Bachet
Session: Poster session 15